First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease

AIM To compare the one-week clinical effects of single doses of dexlansoprazole and esomeprazole on grades A and B erosive esophagitis.METHODS We enrolled 175 adult patients with gastroesophageal reflux disease(GERD). The patients were randomized in a 1:1 ratio into two sequence groups to define the order in which they received single doses of dexlansoprazole(n = 88) and esomeprazole(n = 87) for an intention-to-treat analysis. The primary endpoints were the complete symptom resolution(CSR) rates at days 1, 3, and 7 after drug administration.RESULTS Thirteen patients were lost to follow-up, resulting in 81 patients in each group for the per-protocol analysis. The CSRs for both groups were similar at days 1, 3 and 7. In the subgroup analysis, the female patients achieved higher CSRs in the dexlansoprazole group than in the esomeprazole group at day 3(38.3% vs 18.4%, P = 0.046). An increasing trend toward a higher CSR was observed in the dexlansoprazole group at day 7(55.3% vs 36.8%, P = 0.09). In the esomeprazole group, female sex was a negative predictive factor for CSR on post-administration day 1 [OR =-1.249 ± 0.543; 95%CI: 0.287(0.099-0.832), P = 0.022] and day 3 [OR =-1.254 ± 0.519; 95%CI: 0.285(0.103-0.789), P = 0.016]. Patients with spicy food eating habits achieved lower CSRs on day 1 [37.3% vs 21.4%, OR =-0.969 ± 0.438; 95%CI: 0.380(0.161-0.896), P = 0.027]. CONCLUSION The overall CSR for GERD patients was similar at days 1-7 for both the dexlansoprazole and esomeprazole groups, although a higher incidence of CSR was observed on day 3 in female patients who received a single dose of dexlansoprazole.

Complete cohomology for complexes with finite Gorenstein AC-projective dimension

We study complete cohomology of complexes with finite Gorenstein AC-projective dimension. We show first that the class of complexes admitting a complete level resolution is exactly the class of complexes with finite Gorenstein AC-projective dimension. This lets us give some general techniques for computing complete cohomology of complexes with finite Gorenstein AC- projective dimension. As a consequence, the classical relative cohomology for modules of finite Gorenstein AC-projective dimension is extended. Finally, the relationships between projective dimension and Gorenstein AC-projective dimension for complexes are given.

Gorenstein Injective and Injective Complete Cohomological Dimensions of Groups

Using Nucinkis＇s injective complete cohomological functors, we assign a numerical invariant to each group P, called the injective complete cohomological dimension of F, denoted by iccd P. We study this dimension and investigate its properties. Also, we define the Gorenstein injective dimension of the group F, which is denoted by Gid F. We show that Gid F is related to iccd F, as well as to spli and silp invariants of Gedrich and Gruenberg. In particular, it is shown that iccd P is a refinement of Gid P. In addition, we show that silp F = spli F 〈 ∞if and only if the Shapiro lemma holds for injective complete cohomology.

Vanishing of Tate Homology - An Application of Stable Homology for Complexes

It has been proved that the vanishing of Tare homology is a sufficient condition for the derived depth formula to hold in [J. Pure Appl. Algebra, 219, 464-481 （2015）]. In this paper, we inves- tigate when Tate homology vanishes by studying the stable homology theory for complexes. Properties such as the balancedness and vanishing of stable homology for complexes are studied. Our results show that the vanishing of this homology can detect finiteness of homological dimensions of complexes and regularness of rings.